- ISIN
- US63009J1079
- CUSIP
- 63009J107
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 11, 2020
Highlights
- Market Cap
- $1.94B
- Enterprise Value
- $1.99B
- Total Revenue (TTM)
- €47.94M
- Gross Profit (TTM)
- €47.94M
- EBITDA (TTM)
- -€55.82M
- Year Range
- $6.09 - $57.14
- Target Price
- $26.00
- ROA (TTM)
- -125.61%
- ROE (TTM)
- 100.75%
- Avg. Volume (1M)
- 127K
- Avg. Volume Value (1M)
- $4.97M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NBTX Performance Chart
Nanobiotix S.A. (NBTX) is up 66.0% since the beginning of the year. At $38 per share, NBTX is trading 32.8% below its 52-week high of $57. Investors who bought $1,000 worth of NBTX shares 5 years ago would now be looking at an investment worth $2,607.
Loading charts...
Compare this symbol against anything
Returns By Period
Nanobiotix S.A. (NBTX) has returned 66.03% so far this year and 464.49% over the past 12 months.
Nanobiotix S.A.
- 1D
- -4.41%
- 1M
- -0.04%
- 6M
- 82.79%
- YTD
- 66.03%
- 1Y
- 464.49%
- 3Y*
- 72.87%
- 5Y*
- 21.12%
- 10Y*
- —
- ALL TIME*
- 14.22%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
NBTX Monthly Returns History
Based on dividend-adjusted daily data since Dec 11, 2020, NBTX's average daily return is +0.28%, while the average monthly return is +4.09%. At this rate, an investment would double in approximately 1.4 years.
Historically, 47% of months were positive and 53% were negative. The best month was May 2023 with a return of +114.0%, while the worst month was Apr 2023 at -39.3%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 12 months.
On a daily basis, NBTX closed higher 43% of trading days. The best single day was May 5, 2023 with a return of +229.1%, while the worst single day was Apr 25, 2023 at -40.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.17% | 47.81% | -0.55% | 12.15% | 16.70% | -6.68% | 1.82% | 66.03% | |||||
| 2025 | 21.43% | 0.72% | 1.99% | -5.31% | 20.94% | 15.37% | 45.98% | 29.55% | 111.18% | 10.48% | -0.86% | 11.74% | 705.57% |
| 2024 | 4.40% | -17.76% | 4.00% | -10.15% | 20.55% | -28.98% | 8.40% | 10.70% | -4.17% | -27.65% | -22.36% | -11.15% | -60.58% |
| 2023 | 16.24% | -17.49% | 0.14% | -39.29% | 114.02% | 10.70% | 52.07% | 18.55% | -4.27% | -22.86% | -16.96% | 29.88% | 98.37% |
| 2022 | -5.56% | -1.44% | -1.33% | -20.70% | -11.36% | -27.34% | -38.95% | 71.98% | -11.28% | 11.86% | -0.25% | -7.09% | -54.69% |
| 2021 | 1.03% | -0.32% | -9.49% | 2.86% | 10.67% | -19.51% | 6.86% | -14.44% | -9.84% | -8.19% | -18.70% | -4.48% | -50.91% |
Benchmark Metrics
Nanobiotix S.A. has an annualized alpha of 74.12%, beta of 1.10, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since December 11, 2020.
- This stock captured 114.38% of S&P 500 Index gains and 112.76% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 74.12%
- Beta
- 1.10
- R²
- 0.02
- Upside Capture
- 114.38%
- Downside Capture
- 112.76%
Return for Risk
Risk / Return Rank
NBTX ranks 97 for risk / return — above 97% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Nanobiotix S.A. (NBTX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NBTX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.86 | ||
| Sortino ratioReturn per unit of downside risk | +1.68 | ||
| Omega ratioGain probability vs. loss probability | 1.46 | 1.25 | +0.20 |
| Calmar ratioReturn relative to maximum drawdown | 9.15 | 2.00 | +7.15 |
| Martin ratioReturn relative to average drawdown | 19.20 | 8.49 | +10.71 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Nanobiotix S.A.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Nanobiotix S.A. was 89.94%, occurring on May 1, 2023. Recovery took 608 trading sessions.
The current Nanobiotix S.A. drawdown is 30.30%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-89.94%May 2023 | 2y 3mo | 2y 5mo | 4y 8moJan 2021 - Oct 2025 | — |
-50.25%Oct 2025 | 13d | 4mo 3d | 4mo 16dOct 2025 - Feb 2026 | — |
-39.08%Jun 2026 | 26d | — | 2mo 19dMay 2026 - now | — |
-27.66%Mar 2026 | 10d | 1mo 17d | 1mo 27dMar 2026 - May 2026 | — |
-21.10%Oct 2025 | 1d | 3d | 3dOct 2025 - Oct 2025 | — |
Drawdown Indicators
| NBTX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.94% | -56.78% | -33.16% |
Max Drawdown (1Y)Largest decline over 1 year | -50.25% | -9.10% | -41.15% |
Max Drawdown (3Y)Largest decline over 3 years | -73.88% | -18.90% | -54.98% |
Max Drawdown (5Y)Largest decline over 5 years | -86.00% | -25.43% | -60.57% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -30.30% | -1.58% | -28.72% |
Average DrawdownAverage peak-to-trough decline | -56.78% | -10.70% | -46.08% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.89% | 2.14% | +21.75% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Nanobiotix S.A. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Nanobiotix S.A. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NBTX
Add Nanobiotix S.A. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NBTX